Thrilled to share our latest publication Link to download article @EinsteinMed @ae_cancercenter @MontefioreNYC @NatureComms.

Great to see this paper published and thanks for the opportunity to be part of it! Congratulations to Anna, Luca and the whole team for this exciting work!.

without broadly impairing lysosomal function — a major step forward for autophagy-based cancer therapies and other conditions driven by abnormal upregulation of CMA. Huge congratulations to Mericka McCabe, PhD for leading this study and to the whole team!!.

that disrupts this complex 3) CIM7 selectively inhibits CMA (not macroautophagy), 4) Preferential activity in cancer cells with no observed toxicity 5) Demonstrates in vivo tumor growth inhibition in NSCLC models. This work provides a new pharmacologic strategy to target CMA.

In this study, we identify NCoR1/RARα interaction as a druggable mechanism and report the first-in-class, selective CMA inhibitor that lead to reduced tumor growth. Key Highlights: 1)RARα/NCoR1 interaction transcriptionally regulates CMA in NSCLC 2)CIM7, a novel small molecule.

Excited to share our latest work on selective autophagy inhibition in cancer published @EmboMolMed a collaborative work from Ana Maria Cuervo and Evris Gavathiotis labs @EinsteinMed @ae_cancercenter.

Novel Treatment Strategy for Non-Small Cell Lung Cancer @EmboMolMed @EinsteinMed @MontefioreNYC

A wonderful gathering to celebrate and bid farewell to Mericka McCabe. Your remarkable achievements and passion to advancing science and policy have inspired us! Wishing you every success in your next chapter - we know you’ll do amazing things! @EinsteinMed @MontefioreNYC

Delighted to contribute to this article on resistance mechanisms and therapeutic strategies targeting CDK4/6 kinases, and to collaborate with an amazing team driving new advancements in this field! @EinsteinMed @MontefioreNYC

RT @Poulikos: Our review article, "Resistance Mechanisms and Therapeutic Strategies for CDK4/6 Kinase Targeting in Cancer," is out today in….

RT @EinsteinAging: New publication from @LiGanLab @WeillCornell in collaboration with some of our Einstein groups! @SimoneSidoli @AMCuervoL….

Congratulations to Oi Wei Mak for winning an award @ae_cancercenter retreat. She presented her research on developing an integrative computational and experimental platform for allosteric drug discovery, focusing on BCL-2 proteins, an exciting step forward. Great job, Oi Wei👏👏

Looking forward to building on these findings, gaining deeper insights into the basic mechanisms related to mitochondria in senescence, and further developing our mitofusin inhibitors into a new class of drugs for senescence-associated pathologies.

previously reported here attenuates the SASP, revealing that mt-dsRNA/MAVS/MFN1 axis as a key driver of the SASP and a novel therapeutic target for senescence-associated diseases.

A key finding is that mitochondrial dynamics protein mitofusin MFN1, but not MFN2, is important for the activation of the mt-dsRNA/MAVS/SASP axis and, accordingly, genetic or pharmacologic MFN1 inhibition with our mitofusin inhibitor.

through activating innate immune sensors (RIGI and MDA5) and the inflammatory signaling platform MAVS. Inhibition of mitochondrial RNA polymerase reduces SASP and systemic inflammation associated to senescence.

The paper reports that mitochondrial double-stranded RNA (mt-dsRNA) release to the cytosol is a general feature of senescent cells and a critical driver of their inflammatory secretome, known as senescence-associated secretory phenotype (SASP),.

Super exciting publication from our collaborative work with Manuel Serrano lab @NatureComms Link here Congratulations to all authors for this achievement! @EinsteinMed @MontefioreNYC @EinsteinAging @ae_cancercenter @CDI_Einstein.

Congratulations Dr. Mericka McCabe! @MccabeMericka Proud to have hooded you @EinsteinMed @EinsteinPhD Commencement. Wishing you all the best for a bright future!

My gratitude extends to the renowned speakers for sharing their invaluable insights as well as to all attendees for their participation and engagement.